Breaking News Instant updates and real-time market news.

CI

Cigna

$160.51

(0.00%)

, BBBY

Bed Bath & Beyond

$11.54

(0.00%)

09:40
07/11/19
07/11
09:40
07/11/19
09:40

Unusually active option classes on open July 11th

Unusual total active option classes on open include: Cigna (CI), Bed Bath & Beyond (BBBY), Fastenal (FAST), CVS Health (CVS), Nutanix (NTNX), Anheuser Busch (BUD), Delta Air Lines (DAL), Walgreen Boots (WBA), UnitedHealth (UNH), and Centene (CNC).

CI

Cigna

$160.51

(0.00%)

BBBY

Bed Bath & Beyond

$11.54

(0.00%)

FAST

Fastenal

$31.23

(0.00%)

CVS

CVS Health

$55.39

(0.00%)

NTNX

Nutanix

$25.85

(0.00%)

BUD

AB InBev

$91.43

(0.00%)

DAL

Delta Air Lines

$59.49

(0.00%)

WBA

Walgreens Boots Alliance

$55.57

(0.00%)

UNH

UnitedHealth

$247.48

(0.00%)

CNC

Centene

$51.21

(0.00%)

  • 11

    Jul

  • 11

    Jul

  • 18

    Jul

  • 23

    Jul

  • 25

    Jul

  • 25

    Jul

  • 01

    Aug

  • 05

    Aug

  • 06

    Aug

  • 07

    Aug

  • 09

    Sep

CI Cigna
$160.51

(0.00%)

07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/25/19
SBSH
06/25/19
NO CHANGE
SBSH
Molina, Centene have most at stake from Texas Medicaid awards, says Citi
Citi analyst Ralph Giacobbe noted that Texas' "highly anticipated" STAR+PLUS contract for the states' higher acuity Medicaid members is expected to be awarded this Friday, June 28. Among the incumbents in the state, Molina (MOH) and Centene (CNC) have the most at stake, as their respective STAR+PLUS earnings contribute about 7% and 2%, respectively, of his and consensus estimates, Giacobbe tells investors. He estimates that the other incumbents - Anthem (ANTM), Cigna (CI) and UnitedHealth (UNH) - have 1% or less of their earnings at stake, adding that investor expectations are for the incumbents to largely retain business.
06/20/19
JEFF
06/20/19
NO CHANGE
JEFF
Amazon's PillPack looking to bypass PBMs, says Jefferies
Jefferies analyst Brian Tanquilut says his review of documents related to a case filed by CVS Health (CVS), which seeks to prevent a former CVS executive from joining PillPack, shows that Amazon.com (AMZN) is seeking to develop a service offering that would bypass pharmacy benefit managers and contract directly with payors. While it is difficult to predict the success of PillPack's efforts to bypass existing prescription payment structures, the court disclosure is a potential negative for PBMs like CVS Health, UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI), Tanquilut tells investors in a research note.
06/03/19
SBSH
06/03/19
NO CHANGE
Target $203
SBSH
Buy
Cigna price target lowered to $203 from $228 at Citi
Citi analyst Ralph Giacobbe lowered his price target for Cigna to $203 from $228 to reflect the recent "re-rating" of the managed care group. Cigna is now a "show me" story that will take some time, Giacobbe tells investors in a research note. The analyst, however, remains bullish on the shares following the company's analyst day and he keeps a Buy rating on the name.
BBBY Bed Bath & Beyond
$11.54

(0.00%)

07/11/19
JEFF
07/11/19
NO CHANGE
Target $13
JEFF
Hold
Bed Bath & Beyond price target lowered to $13 from $17 at Jefferies
Jefferies analyst Jonathan Matuszewski lowered his price target for Bed Bath & Beyond to $13 from $17 saying the company's sales and margins continue to disappoint. The analyst prefers to remain on the sidelines "until evidence of inflecting trends." He keeps a Hold rating on the name following last night's fiscal Q1 results.
07/11/19
BARD
07/11/19
NO CHANGE
Target $13
BARD
Neutral
Bed Bath & Beyond price target lowered to $13 from $18 at Baird
Baird analyst Peter Benedict lowered his price target for Bed Bath & Beyond to $13 from $18 and maintained a Neutral rating following the company's quarterly results. In a research note to investors, Benedict says that while adjusted EPS exceeded expectations, a lower tax rate/share count was required to offset an EBIT shortfall. While management remains focused on stabilizing sales in fiscal 2020, Benedict says he sees "little evidence" of an inflection on the horizon without sacrificing margins.
07/11/19
GSCO
07/11/19
INITIATION
Target $11
GSCO
Sell
Bed Bath & Beyond initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Kate McShane started Bed Bath & Beyond with a Sell rating and $11 price target. Weak in-store trends and over-reliance on coupons as a traffic driver have led to significant pressure on sales and margins, McShane tells investors in a research note. She expects expect Bed Bath & Beyond will face ongoing sales declines and market share losses resulting from a high level of competition in the industry and continued challenges with its store fleet.
07/11/19
LOOP
07/11/19
NO CHANGE
Target $12
LOOP
Hold
Bed Bath & Beyond off to 'rough start' in FY19, says Loop Capital
Loop Capital analyst Anthony Chukumba kept his Hold rating and $12 price target on Bed Bath & Beyond, saying the company is starting FY19 with the "worst comparable sales drop in recent memory", while the degradation of its gross margins and SG&A expense deleverage resulted in a "substantial" decline in its earnings. The analyst adds that the management's focus on near-term strategic priorities is "sensible", but given the lack of permanent senior management, he sees Bed Bath & Beyond stock as a "show me" story.
FAST Fastenal
$31.23

(0.00%)

06/14/19
BUCK
06/14/19
NO CHANGE
Target $31
BUCK
Neutral
Fastenal estimates cut at Buckingham after management meetings
Buckingham analyst Robert Barry lowered his FY19 and FY20 EPS estimates for Fastenal by about 2% each to factor in April and May sales results and following his visit with management. Management's tone was more cautious and they said they are starting to think about stricter cost discipline, though they still view investing in IT and growth drivers as priorities, according to Barry. He trimmed his price target on Fastenal shares to $31 from $32 and keeps a Neutral rating on the stock.
04/15/19
NRCS
04/15/19
DOWNGRADE
NRCS
Neutral
Fastenal downgraded to Neutral on valuation at Northcoast
Northcoast analyst Ryan Cieslak downgraded Fastenal to Neutral from Buy citing valuation.
05/07/19
WBLR
05/07/19
NO CHANGE
WBLR
William Blair downgrades Fastenal, MSC Industrial, Wesco to Market Perform
William Blair analyst Ryan Merkel downgraded Fastenal (FAST), MSC Industrial (MSM) and Wesco (WCC) to Market Perform from Outperform while maintaining an Outperform rating on Systemax (SYX). With growth challenges rising distributor earnings estimates are too high for 2019 and 2020, Merkel tells investors in a research note. He believes "several industrial indicators are flashing yellow," including global trade volumes, durable goods orders, manufacturing inventory growth, and a strong U.S. dollar. Further, the analyst is concerned by trends in the automotive, oil and gas, mining, and machinery end-markets. Merkel believes stock valuations are risk given his "late-cycle concerns." He believes fair value for Fastenal is $72 per share, fair value for MSC Industrial is $75 per share and fair value for Wesco is $51 per share.
05/07/19
WBLR
05/07/19
DOWNGRADE
WBLR
Market Perform
Fastenal downgraded to Market Perform from Outperform at William Blair
CVS CVS Health
$55.39

(0.00%)

06/18/19
JEFF
06/18/19
NO CHANGE
Target $58
JEFF
Buy
CVS Health share upside limited on lack of catalysts, says Jefferies
Jefferies analyst Brian Tanquilut believes the "muted" reaction to CVS Health's recent articulation of its planned strategic moves and issuance of guidance thru 2022 underscore the "show-me stance" investors continue to take on the name. The analyst does not see any meaningful near-term catalysts that could drive "significant" stock upside over the next 12 months. That said, the stock's downside is "limited by a discounted valuation," Tanquilut tells investors in a research note. He keeps raised his price target for CVS Health to $58 from $57 and keeps a Hold rating on the name.
06/25/19
TIGR
06/25/19
NO CHANGE
TIGR
Tigress Financial sees 'significant upside' in CVS Health
Tigress Financial analyst Ivan Feinseth reiterated a Buy rating on CVS Health, citing the ongoing strength in Pharmacy Services, as well as Retail/LTC growth that continues to drive accelerating business performance. Feinseth sees significant upside in the shares and continues to recommend purchase.
NTNX Nutanix
$25.85

(0.00%)

05/31/19
WBLR
05/31/19
NO CHANGE
WBLR
Outperform
Nutanix shares 'fairly washed out' amid selloff, says William Blair
Following another "disappointing" quarter, Nutanix (NTNX) management pushed out the prospect of a full recovery with Q4 revenue, billings, and earnings guided well below consensus, William Blair analyst Jason Ader tells investors in a research note. The analyst attributes the weakness to weak sales execution, a faster than expected transition to a subscription business model, and increased competition from main rival Dell Technologies (DELL) / VMware (VMW). Ader, however, believes Nutanix shares are "fairly washed out at this point." As such, he sees a favorable risk/reward equation and keeps an Outperform rating on Nutanix.
07/08/19
SBSH
07/08/19
DOWNGRADE
Target $55
SBSH
Sell
NetApp downgraded to Sell from Neutral at Citi
Citi analyst Jim Suva downgraded NetApp (NTAP) to Sell from Neutral and lowered his price target for the shares to $55 from $67. The competitive landscape with Dell (DELL) against the slowing macro environment adds more pressure to the company, Suva tells investors in a research note. The analyst says he's picked up recent competitive pressures against NetApp by Dell, Hewlett-Packard Enterprise (HPE), Pure Storage (PSTG) and Nutanix (NTNX). As a result, Suva expects share and margin pressures for NetApp.
07/11/19
WBLR
07/11/19
NO CHANGE
WBLR
Outperform
Nutanix checks show early signs of an upswing, says William Blair
After Nutanix's business started the calendar year with a six-month "rough patch," recent reseller commentary points to the early stages of an upswing, William Blair analyst Jason Ader tells investors in a research note. The resellers note a "solid pace" to their Nutanix business in the July quarter with a growing number of seven-figure deals, an improving pipeline, and good distribution across commercial and public sector accounts and across workloads, adds the analyst. He finds Nutanix's valuation "compelling" at current share levels and reiterates an Outperform rating on the name.
05/31/19
05/31/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mallinckrodt (MNK) downgraded to Neutral from Overweight at Piper Jaffray with analyst David Amsellem stating last week's developments regarding Acthar in the Medicaid setting, along with as much as a $600M Centers for Medicare & Medicaid Services-related liability, "essentially blew" his prior investment thesis to "smithereens." 2. Nucor (NUE) downgraded to Underperform from Buy at BofA/Merrill with analyst Timna Tanners incorporating a lower near-term forecast for prices, especially for sheet and rebar, and a lower 2021-2022 forecast given expectations for a looming glut in steel. 3. J.Jill (JILL) downgraded to Hold from Buy at Deutsche Bank with analyst Lorraine Hutchinson stating that she expects the stock's multiple to contract due to the company's slower growth. 4. Nutanix (NTNX) downgraded to Neutral from Overweight at Piper Jaffray with analyst Andrew Nowinski citing the company's "continued execution issues," which he attributes partially to increasing competition. 5. Zuora (ZUO) downgraded to Buy from Strong Buy at Needham with analyst Scott Berg saying that the stock could be "dead money" for the next 1-2 quarters, noting that the sales issues are more concerning than the product issues and may require a change in sales leadership. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BUD AB InBev
$91.43

(0.00%)

05/30/19
05/30/19
UPGRADE
Target $92

Buy
AB InBev upgraded to Buy from Hold at Argus
As previously reported, Argus analyst John Eade upgraded AB InBev to Buy with a price target of $92. The analyst notes that the stock has underperformed the broader market over the past 12 months with a 12% decline, even though its recent results have been "solid" with margin expansion and a high-single-digit revenue growth. In addition to the improving financials, Eade expects AB InBev to benefit from the increased demand for premium beers, expanding sales of "near-beer" and nonalcoholic beverages, as well as its current "under-penetration" in emerging markets. The analyst further notes that the company may pursue further accretive acquisitions over time.
05/30/19
ARGS
05/30/19
UPGRADE
ARGS
Buy
AB InBev upgraded to Buy from Hold at Argus
05/22/19
GUGG
05/22/19
NO CHANGE
Target $103
GUGG
Buy
AB InBev named a sector Best Idea, replacing Coca-Cola at Guggenheim
Guggenheim analyst Laurent Grandet named Anheuser-Busch InBev (BUD) his sector Best Idea, replacing Coca-Cola (KO), citing his increased conviction in its U.S. growth following an investor seminar hosted by the company. The analyst, who also sees untapped "premiumization" opportunities and significant potential in emerging markets, raised his FY19, FY20 and FY21 EPS estimates for AB InBev but keeps an unchanged price target of $103 on the stock with a Buy rating.
05/03/19
MAXM
05/03/19
INITIATION
Target $21
MAXM
Buy
Craft Brew assumed with a Buy at Maxim
Maxim analyst Anthony Vendetti assumed Craft Brew Alliance (BREW) with a Buy rating and a price target of $21, saying he expects the company's revenue to accelerate in 2019 thanks mostly to the increased marketing for its flagship Kona brand. The analyst also cites Craft Brew's relationship with InBev (BUD) and points to its option to make a qualifying acquisition offer at $24.50 per share by August 23rd.
DAL Delta Air Lines
$59.49

(0.00%)

07/03/19
SPHN
07/03/19
INITIATION
Target $70
SPHN
Overweight
Delta Air Lines re-assumed with an Overweight at Stephens
Stephens analyst Jack Atkins re-assumed coverage of Delta Air Lines with an Overweight rating and $70 price target, up from his prior target of $68. He thinks the U.S. passenger airline market is "solidly outperforming the doom and gloom expectations that many had at the start of the year" and cites Delta's fare momentum, cost controls and recently extended co-branded credit card agreement as reasons for his bullish view.
06/13/19
JPMS
06/13/19
NO CHANGE
JPMS
JPMorgan notes airline fare hike, doesn't see domestic 'resilience' as priced in
JPMorgan analyst Jamie Baker said he was "surprised" to see domestic fares rising again after a price hike five weeks ago, noting that Southwest (LUV) joined with an increase overnight. Given "the crescendo of inquiries as to why, and nary a question on fares," Baker said he is confident that increased domestic fare resilience is not yet priced into airline stocks. Other publicly traded airlines include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Spirit Airlines (SAVE) and United Continental (UAL).
07/03/19
STFL
07/03/19
NO CHANGE
Target $90
STFL
Buy
Delta one of biggest beneficiaries of longer MAX grounding, says Stifel
Stifel analyst Joseph DeNardi noted that Delta's (DAL) updated Q2 guidance yesterday was "strong across the board," pointing out that domestic load factor for the quarter of 89% benefited from the fact that the grounding of Boeing's (BA) MAX fleet is keeping industry capacity growth constrained. He sees Delta as one of the biggest beneficiaries, second only to Spirit Airlines (SAVE) and Alaska Air (ALK), as the grounding extends further out given the company's lack of exposure and the industry's competitive capacity dynamics. DeNardi maintains a Buy rating and $90 price target on Delta shares.
06/13/19
JPMS
06/13/19
NO CHANGE
JPMS
American, Southwest raised domestic rates in last two days, says JPMorgan
JPMorgan analyst Jamie Baker said American Airlines (AAL) took a "plain vanilla" domestic fare increase of $5 one-way yesterday morning, which was followed by what looks like a system-wide increase from Hawaiian (HA) and a "substantive" Lower 48 increase from Southwest (LUV). He was not expecting another increase so soon after the industry took a broad-based domestic increase in the second week of May, noted Baker, who thinks evidence of domestic demand and potential Q2 guidance increases could reverse "recent apathy" towards the airline space. Other publicly traded airlines include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Continental (UAL).
WBA Walgreens Boots Alliance
$55.57

(0.00%)

06/28/19
06/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 1. Walgreens Boots Alliance (WBA) downgraded to Neutral from Outperform at Credit Suisse with analyst A.J. Rice saying Walgreens cut its guidance for FY19 and reduced its long-term EPS growth target to the mid-to-high single digits and said he would want to see clear indications that visibility on earnings growth is improving before considering raising his rating. 2. Biogen (BIIB) downgraded to Neutral from Overweight at Piper Jaffray with analyst Christopher Raymond saying Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term." 3. Live Nation (LYV) downgraded to Sell from Neutral at Citi with analyst Jason Bazinet saying he still likes the company's growth prospects and "consistent" operating performance. 4. Arrowhead (ARWR) downgraded to Neutral from Overweight at Cantor Fitzgerald with analyst Elemer Piros saying he views the stock as fairly valued. 5. Darden (DRI) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/19
FBCO
06/28/19
DOWNGRADE
Target $60
FBCO
Neutral
Walgreens Boots Alliance assumed at Neutral from Outperform at Credit Suisse
Credit Suisse analyst A.J. Rice assumed coverage of Walgreens Boots Alliance with a Neutral rating, down from the firm's prior Outperform rating, and set a $60 price target on the stock, down from the firm's prior $70 target. Rice noted that Walgreens cut its guidance for FY19 and reduced its long-term EPS growth target to the mid-to-high single digits and said he would want to see clear indications that visibility on earnings growth is improving before considering raising his rating.
06/27/19
RAJA
06/27/19
NO CHANGE
RAJA
Walgreens Boots Alliance Q3 better than expected, says Raymond James
Raymond James analyst John Ransom maintained a Market Perform rating on Walgreens Boots Alliance after the company reported Q3 earnings results that were modestly better than expected, driven by strong pharmacy sales, along with "roughly flat" FY19 guidance which the analyst believes reflects ongoing headwinds from reimbursement and market challenges.
05/14/19
RAJA
05/14/19
NO CHANGE
RAJA
Walgreens could target Amerisource, LabCorp if it seeks M&A, says Raymond James
Raymond James analyst John Ransom said he thinks that "the temptation" for Walgreens (WBA) to do "something" in terms of M&A will grow over time and the "something" it may consider could include either acquiring AmerisourceBergen (ABC) or LabCorp (LH). His analysis points to LabCorp being a less complicated, "but much less accretive," deal, said Ransom. Given Walgreens' existing ownership of about a 26% stake in AmerisourceBergen, he estimates 16% accretion from buying the company for $95 per share in cash if he assumes $500M of synergies and $2B of opioid fines financed with debt, the analyst tells investors. Though such a deal would make financial sense, he does not think investors would "be overly excited about the strategic upside," Ransom tells investors. While he argues that LabCorp "offers more strategic upside," such a hypothetical deal also has less financial benefit, according to Ransom.
UNH UnitedHealth
$247.48

(0.00%)

06/24/19
ADAM
06/24/19
NO CHANGE
Target $39
ADAM
Buy
HMS Holdings' recent weakness overdone, says Canaccord
Canaccord analyst Richard Close said he believes the recent weakness in HMS Holdings (HMSY) shares is overdone. The weakness was attributed to reports UnitedHealth (UNH) will be buying Equian, a payment integrity services provider. The analyst believes the pullback was based on fears of increased competition and potential risk that HMS will lose UnitedHealth as a customer. He said although both provide integrity services to healthcare, Equian does not provide COB services, which accounted for 66.4% of HMS's revenue. As a result, he does not believe this transaction should raise any concerns. Close reiterated his Buy rating and $39 price target on HMS Holdings shares.
07/08/19
BOFA
07/08/19
NO CHANGE
Target $75
BOFA
Neutral
Inspire Medical price target raised to $75 from $65 at BofA/Merrill
BofA/Merrill analyst Bob Hopkins raised his price target for Inspire Medical (INSP) to $75 from $65 after the company announced that United Healthcare (UNH) will provide coverage for Inspire's obstructive sleep apnea therapy as of August 1. In a research note to investors, Hopkins, who maintains a Neutral rating on Inspire, says it takes about 2-4 months for a patient insured by United to work their way through the prior-authorization, but Inspire now estimates that it will take just five days to get approval if a patient meats the restrictions set by United. Hopkins sees potential upside to Street numbers later in 2019 and 2022, but believes his positive outlook is largely reflected in the current stock price.
CNC Centene
$51.21

(0.00%)

06/17/19
06/17/19
NO CHANGE

Centene growth undervalued, political risks overdone, says Piper Jaffray
Centene's valuation multiple has compressed from 17 times to 11 times on healthcare reform risk that has little chance of coming to fruition, Piper Jaffray analyst Sarah James tells investors in a research note. The analyst believes the core Centene business has potential for long-term annual earnings growth in the 20% range. She believes the company's growth is being undervalued while political risks are overdone. The analyst calls Centene a top pick and keeps an Overweight rating on the name with an $80 price target.
07/10/19
SPHN
07/10/19
NO CHANGE
SPHN
Overweight
Centene 'a clear winner' in Oregon Managed Medicaid awards, says Stephens
Stephens analyst Scott Fidel noted that Oregon announced awards for the state's $6B managed Medicaid program, calling Centene "a clear winner" as it retained Lane county, where it maintains essentially all of its current 88,000 Medicaid members in the state, and added three other counties that serve 36% of the state's current managed Medicaid membership. Fidel, who notes the new contracts are expected to begin on Jan. 1, 2020, keeps an Overweight rating on Centene shares.
06/03/19
CANT
06/03/19
NO CHANGE
Target $83
CANT
Overweight
Centene weakness due to Humana disclosure 'overdone,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper notes that Humana (HUM) released an 8-K filing confirming it will not make a proposal to acquire Centene (CNC). With speculation around Humana's involvement casting doubt on Centene's pending merger with WellCare (WCG), the analyst says the news increases his confidence that the merger will be completed by the third quarter of 2020, and continues to believe that the company's merger with WellCare makes sense and should create significant value. Halper expects Centene-WellCare will have to divest certain Medicaid assets given the overlap in some states, but he believes that the acquisition will ultimately be completed by the company's estimated timeline. The analyst has an Overweight rating and $83 price target on Centene's shares.

TODAY'S FREE FLY STORIES

SFTBF

SoftBank

$0.00

(0.00%)

, SFTBY

SoftBank

$0.00

(0.00%)

17:59
08/18/19
08/18
17:59
08/18/19
17:59
Periodicals
Softbank plans to lend up to $20B to employees to invest in new fund, WSJ says »

Softbank is planning to…

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:50
08/18/19
08/18
16:50
08/18/19
16:50
Periodicals
Trump administration to give Huawei more time to work with U.S. clients,WSJ says »

The Trump administration…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JSAIY

J Sainsbury

$0.00

(0.00%)

16:46
08/18/19
08/18
16:46
08/18/19
16:46
Periodicals
J Sainsbury's not talking to internal candidates for CEO succession,Reuters says »

J Sainsbury's is not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$219.92

4.27 (1.98%)

16:39
08/18/19
08/18
16:39
08/18/19
16:39
Hot Stocks
Tesla relaunching solar-panel business with no-contract rentals »

Tesla is now offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 23

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

16:14
08/18/19
08/18
16:14
08/18/19
16:14
Periodicals
White House says no recession in sight, Reuters reports »

White House officials…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$288.79

4.12 (1.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$89.46

0.91 (1.03%)

16:11
08/18/19
08/18
16:11
08/18/19
16:11
Periodicals
Novartis executive sold shares before data manipulation made public,Reuters says »

An unnamed Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

MO

Altria Group

$46.48

1 (2.20%)

16:08
08/18/19
08/18
16:08
08/18/19
16:08
Periodicals
CDC investigating lung illness linked to e-cigarette use, Reuters reports »

The Centers for Disease…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFB

CrossFirst Bancshares

$14.61

(0.00%)

, JFU

9F Inc

$10.09

0.52 (5.43%)

08:48
08/18/19
08/18
08:48
08/18/19
08:48
On The Fly
Opening Day: CrossFirst rises after setting IPO share price lower than expected »

Shares of CrossFirst…

CFB

CrossFirst Bancshares

$14.61

(0.00%)

JFU

9F Inc

$10.09

0.52 (5.43%)

NET

Cloudflare

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

SDC

SmileDirectClub

$0.00

(0.00%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 27

    Oct

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$19.94

0.16 (0.81%)

17:57
08/16/19
08/16
17:57
08/16/19
17:57
Hot Stocks
Breaking Hot Stocks news story on Wendy's »

Trian Fund lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BRY

Berry Petroleum

$8.59

0.39 (4.76%)

17:54
08/16/19
08/16
17:54
08/16/19
17:54
Syndicate
Breaking Syndicate news story on Berry Petroleum »

Berry Petroleum files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSWI

CSW Industrials

$70.20

1.92 (2.81%)

17:52
08/16/19
08/16
17:52
08/16/19
17:52
Hot Stocks
CSW Industrials CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$3.03

0.135 (4.66%)

17:49
08/16/19
08/16
17:49
08/16/19
17:49
Hot Stocks
Oasis Petroleum CEO buys 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EE

El Paso Electric

$66.41

0.005 (0.01%)

17:45
08/16/19
08/16
17:45
08/16/19
17:45
Hot Stocks
El Paso Electric director Wertheimer sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$165.07

2.81 (1.73%)

17:42
08/16/19
08/16
17:42
08/16/19
17:42
Hot Stocks
Honeywell CEO sells 7.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.